Abstract:Although Coronavirus disease 2019 (COVID-19) vaccinations are generally recommended for persons with epilepsy (PwE), a significant vaccination gap remains due to patient concerns over the risk of post-vaccination seizure aggravation (PVSA). In this single-centre, retrospective cohort study, we aimed to determine the early (7-day) and delayed (30-day) risk of PVSA, and to identify clinical predictors of PVSA among PwE. Adult epilepsy patients aged ≥18 years without a history of COVID-19 infection were recruited from a specialty epilepsy clinic in early 2022. Demographic, epilepsy characteristics, and vaccination data were extracted from a centralized electronic patient record. Seizure frequency before and after vaccination, vaccination-related adverse effects, and reasons for or against vaccination were obtained by a structured questionnaire. A total of 786 PwEs were included, of which 27.0% were drug-resistant. At the time of recruitment, 74.6% had at least 1 dose of the COVID-19 vaccine. Subjects with higher seizure frequency (p < 0.0005), on more anti-seizure medications (p = 0.004), or had drug-resistant epilepsy (p = 0.001) were less likely to be vaccinated. No significant increase in seizure frequency was observed in the early (7 days) and delayed phases (30 days) after vaccination in our cohort. On the contrary, there was an overall significant reduction in seizure frequency 30 days after vaccination (1.31 vs. 1.89, t = 3.436; p = 0.001). This difference was seen in both types of vaccine (BNT162b2 and CoronaVac) and drug-resistant epilepsy, but just missed significance for the second dose (1.13 vs. 1.87, t = 1.921; p = 0.055). Only 5.3% had PVSA after either dose of vaccine. Higher pre-vaccination seizure frequency of ≥1 per week (OR 3.01, 95% CI 1.05–8.62; p = 0.04) and drug-resistant status (OR 3.32, 95% CI 1.45–249 7.61; p = 0.005) were predictive of PVSA. Meanwhile, seizure freedom for 3 months before vaccination was independently associated with a lower risk of PVSA (OR 0.11, 95% CI 0.04–0.28; p < 0.0005). This may guide epilepsy treatment strategies to achieve better seizure control for at least 3 months prior to vaccination. As COVID-19 shifts to an endemic phase, this study provides important data demonstrating the overall safety of COVID-19 vaccinations among PwE. Identification of high-risk patients with subsequent individualized approaches in treatment and monitoring strategies may alleviate vaccination hesitancy among PwE.

Effect of inactivated COVID-19 vaccines on seizure frequency in patients with epilepsy: A multicenter, prospective study

Effects of coronavirus disease 2019 vaccination on seizures in patients with epilepsy

Risk of Seizure Aggravation after COVID-19 Vaccinations in Patients with Epilepsy

COVID-19 vaccination for patients with epilepsy: A Chinese expert consensus

COVID‐19 vaccine take‐up rate and safety in adults with epilepsy: Data from a multicenter study in China

Safety and tolerability of COVID-19 vaccine in children with epilepsy: a prospective, multicenter study

COVID-19 vaccination hesitancy and safety among adult people with epilepsy in eastern China

Vaccination against COVID-19 and potential protective effects on seizure recurrence in children with epilepsy: A cross-sectional survey

Predictors and Prevalence of COVID-19 Vaccination in Patients with Focal Epilepsy Following Resection Surgery.

Association of new onset seizure and COVID‐19 vaccines and long‐term follow‐up: A systematic review and meta‐analysis

Association of New-Onset Seizures With SARS-CoV-2 Vaccines

Analysis of new-onset seizures following use of COVID-19 vaccinations in children based on VAERS

COVID-19 vaccination for patients with benign childhood epilepsy with centrotemporal spikes

Attitudes to Being Vaccinated Against COVID-19: A Survey of People With Epilepsy in China

COVID-19 vaccination uptake in children with epilepsy and vaccine hesitancy among their parents: a survey

Effect of COVID-19 on seizures and patient behavior in people with epilepsy

COVID-19-Induced Seizures: A Meta-Analysis of Case Series and Retrospective Cohorts

Prevalence and Risk Factors of Anxiety and Depression in Adult Patients with Epilepsy: a Multicenter Survey-Based Study.

Epilepsy and the risk of COVID‐19‐related hospitalization and death: A population study

Safety of inactivated COVID-19 vaccines in autoimmune encephalitis: a real-world cross-sectional survey

Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis